Left ventricular transmural systolic function by high-sensitivity velocity measurement "phased-tracking method" across the septum in doxorubicin cardiomyopathy

Ultrasound in Medicine and Biology

Volumn 28, Issue 11-12, 2002, Pages 1395-1403

  Koiwa, Yoshiro ^a   Kanai, Hiroshi ^b   Hasegawa, Hideyuki ^b   Saitoh, Yoshiko ^a   Shirato, Kunio ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

Doppler measurement; Doxorubicin cardiomyopathy; Intramyocardial velocity; Myocardial layer thickening; Transmural systolic function

Indexed keywords

HEALTH CARE; NONINVASIVE MEDICAL PROCEDURES; ULTRASONIC APPLICATIONS;

TRANSMURAL SYSTOLIC FUNCTIONS (TSF);

CARDIOLOGY;

DOXORUBICIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOXORUBICIN CARDIOMYOPATHY; DRUG INDUCED DISEASE; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE TENSION; HUMAN; MALE; MEASUREMENT; PRIORITY JOURNAL; SYSTOLE;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHIES; DOXORUBICIN; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEART SEPTUM; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; SYSTOLE; VENTRICULAR FUNCTION, LEFT;

EID: 0346668282     PISSN: 03015629     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-5629(02)00644-0     Document Type: Article

References (28)

1. Bogaert J., Maes A., Van de Werf F., et al. Functional recovery of subepicardial myocardial tissue in transmural myocardial infarction after successful reperfusion. Circulation. 99:1999;36-43.
2. Bolli R., et al. Disparity of epicardial and endocardial function during ischemia and reperfusion. Circulation. 70:1984;260. (Suppl.2).
3. Bristow M.R., Mason J.W., Billingham M.E., Daniels J.R. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J. 102:1981;709-718.
4. Choi B.W., Canthy M.C., Palmeri S.T., et al. Serial systolic and diastolic left ventricular function in doxorubicin cardiomyopathy. Circulation. 78:(Suppl. 2):1988;456.
5. Colonna P., Montisci R., Galiuto L., Meloni L., Illiceto S. Effects of acute ischemia on intramyocardial contraction heterogeneity. Eur Heart J. 20:1999;327-337.
6. Dong S.J., MacGregor J.H., Crawley A.P., et al. Left ventricular wall thickness and regional systolic function in patients with hypertrophic cardiomyopathy A three-dimensional tagged magnetic resonance imaging study . Circulation. 90:1994;1200-1209.
7. Donovan C.L., Armstrong W.F., Bach D.S. Quantitative Doppler tissue imaging of the left ventricular myocardium Validation in normal subjects . Am Heart J. 130:1995;100-104.
8. Doroshow J.H. Doxorubicin-induced cardiac toxicity. New Engl J Med. 324:1991;843-845.
9. Dunn J. Doxorubicin-induced cardiomyopathy. J Pediat Oncol Nurses. 11:1994;152-160.
10. Gallagher K.M., Osakada G., Matsuzaki M., et al. Nonuniformity of inner and outer systolic wall thickening in conscious dog. Am J Physiol. 249:1985;H241-H248.
11. Gorcsan J., Strum D.P., Mandarino W.A., Gulati V.K., Pinsky M.R. Quantitative assessment of alterations in regional left ventricular contractility with color-coded tissue Doppler echocardiography. Comparison with sonomicrometry and pressure-volume relations. Circulation. 95:1997;2423-2433.
12. Kanai H., Koiwa Y. Myocardial rapid velocity distribution. Ultrasound Med Biol. 27:2001;481-498.
13. Kanai H., Hasegawa H., Chubachi N., Koiwa Y., Tanaka M. Noninvasive evaluation of local myocardial thickening and its color-coded imaging. IEEE Trans UFFC. 44:1997;752-768.
14. Kanai H., Sato M., Koiwa Y., Chubachi N. Transcutaneous measurement and spectrum analysis of heart wall vibrations. IEEE Trans UFFC. 43:1996;791-810.
15. Koiwa Y., Kamada E., Kanai H., et al. Regional myocardial layer function in doxorubicin cardiomyopathy clinical evaluation using novel Doppler method . Proc IEEE Int Ultrason Sympos. 1/2:1998;1455-1458.
16. Koiwa Y., Kamada H., Inose M., et al. Systolic heterogeneity of transmural myocardial function in normal subjects Physiological functional heterogeneity . Tohoku J Exp Med. 197:2002;183-187. (3).
17. Lipshultz S., Colan S., Gelber R., Sanders S.P. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. New Engl J Med. 324:1991;808-815.
18. Maier S.E., Fisher S.E., Mckinnon G.C., et al. Evaluation of left ventricular segmental wall motion in hypertrophic cardiomyopathy with myocardial tagging. Circulation. 86:1992;1919-1928.
19. Marchandise B., Schroeder E., Bosly A., et al. Early detection of doxorubicin cardiotoxicity Interest of Doppler echocardiographic analysis of left ventricular filling dynamics . Am Heart J. 118:1989;92-98.
20. Morishima I., Matsui H., Mukawa H., et al. Melatonin, a peneal hormone with antioxidant property, protects against adriamycin cardiomyopathy in rat. Life Sci. 63:1998;511-521.
21. Mortensen S.A., Olsen H.S., Baandrup U. Chronic anthracycline cardiotoxicity Hemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease . Br Heart J. 55:1986;274-282.
22. Myers J.H., et al. Inner and outer wall thickening: direct measurement of relative importance to total wall thickening. Clin Res. 32:1984;192A. (2).
23. Myers J.H., Stirling M.C., Choy M., Buda A.J., Gallagher K.P. Direct measurement of inner and outer wall thickening dynamics with epicardial echocardiography. Circulation. 1986;74-172.
24. Palmeri S.T., Bonow R.O., Myers C.E., et al. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. Am J Cardiol. 58:1986;607-613.
25. Sabbah H.N., Marzilli M., Stein P.D. The relative role of subendocardium and subepicardium in left ventricular mechanics. Am J Physiol. 240:1981;H920-H926.
26. Siveski-Iliskovic N., Hill M., Chow D.A., Singal P.K. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation. 91:1995;10-15.
27. Steinherz L., Steinhertz P., Tan C.B. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. J Am Med Assoc. 266:1991;1672-1677.
28. Weesner K.M., Bledsoe M., Chauvenet A., Wofford M. Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer. 68:1991;435-438.